Pink Sheet is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Adapt Pharma Ltd.

www.adaptpharma.com

Latest From Adapt Pharma Ltd.

Teva Has Nasal Naloxone Nod For First US Narcan Rival

Teva has received FDA approval for the first US generic naloxone nasal spray after a 30-month stay linked to ongoing patent litigation expired. Launch plans have not yet been revealed. Meanwhile, the Israeli firm has also introduced the first generic version of VESIcare in the US.

Regulation Generic Drugs

Amid Hype Over Narcan First Generic, A Plea For A Labeling Change

Naloxone distribution programs ask that the cheaper generic injectable formulation have the same community-use language in its label as the nasal spray and auto-injector so they can maximize their distribution efforts.
FDA Neurology

Keeping Track: Approval Of First Intranasal Naloxone Copycat Highlights Otherwise Generic Week

The latest drug development news and highlights from our US FDA Performance Tracker. 
Drug Review Regulation

US FDA Has Model Drug Facts Labels For OTC Naloxone, Needs Switch Proposals

Development of the model DFLs was a first for agency. The project was "part of our broader commitment to addressing the opioid crisis" and should help sponsors with potential naloxone OTC switch NDAs, says Commissioner Scott Gottlieb.

Prescription To Otc Switch Consumer
See All

Company Information

  • Industry
  • Pharmaceuticals
    • Drug Delivery
      • Nasal
    • Specialty Pharmaceuticals
  • Therapeutic Areas
  • Neurology, Nervous System
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • Europe
      • Western Europe
        • Ireland
  • Parent & Subsidiaries
  • Adapt Pharma Ltd.
  • Senior Management
  • Seamus Mulligan, Chmn. & CEO
    David Brabazon, CFO
    Matt Ruth, Chief Commercial Officer
    Eunan Maguire, COO
    Fintan Keegan, CTO
    Ryan Loughlin, Dir., Drug Dev.
  • Contact Info
  • Adapt Pharma Ltd.
    Phone: 1 -6344-172
    45 Fitzwilliam Sq.
    Dublin 2,
    Ireland
Advertisement
Advertisement
UsernamePublicRestriction

Register